Axsome Q3 loss beats estimates as revenue reaches $259.7m
Key points
- Axsome Therapeutics reported a third-quarter net loss of $12.9 million, equivalent to $0.25 per share, beating analyst expectations of a $0.69 loss.
- Revenue reached $259.7 million, exceeding the analyst consensus estimate of $246.4 million.
- Axsome shares have declined 21% since the beginning of 2026 but gained 7% over the past 12 months.
Axsome Therapeutics (NASDAQ:AXSM) reported a third-quarter 2026 net loss of $12.9 million, or $0.25 per share, beating analyst expectations for a loss of $0.69 per share.
The reported loss was smaller than the average estimate from eight analysts surveyed by Zacks Investment Research, while revenue also exceeded market expectations.
The company reported revenue of $259.7 million, compared with the $246.4 million average estimate from seven analysts surveyed by Zacks Investment Research.
Axsome's quarterly net loss amounted to approximately $0.25 per share, representing a smaller loss than analysts had forecast, while revenue exceeded estimates by approximately $13.3 million.
Axsome shares have declined 21% since the beginning of 2026 but gained 7% over the past 12 months; following the announcement, the post-release share-price movement was not independently verified.
Based in New York, Axsome is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders.
Its business includes pharmaceutical research, clinical development and commercial sales, with revenue and earnings performance influenced by its marketed medicines and development programmes.
Frequently asked questions
More from United States
Marvell to acquire Lumentum in $115bn AI deal
Alexander's Q3 FFO reaches $36.3m as revenue hits $72.1m
Pathfinder Bancorp Q3 earnings reach $2.1m as credit costs weigh
Tower Semiconductor Q3 revenue accelerates 33% to $526m
Acadia Realty Q3 NOI rises 10.2% as retail leasing grows
Fox Q1 revenue skyrockets 22% to $4.57bn as advertising grows
